{"name":"Tonix Pharmaceuticals","slug":"tonix","ticker":"TNXP","exchange":"NASDAQ","domain":"tonixpharma.com","description":"Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.","hq":"New York, NY","founded":0,"employees":"142","ceo":"Seth Lederman","sector":"CNS / Vaccines / Immunology","stockPrice":13.55,"stockChange":0.48,"stockChangePercent":3.67,"marketCap":"$192M","metrics":{"revenue":13107000,"revenueGrowth":108.8,"grossMargin":49.3,"rdSpend":44486000,"netIncome":-124021000,"cash":207636992,"dividendYield":0,"peRatio":-2.6,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"TNX-102 SL patent cliff ($0.0B at risk)","drug":"TNX-102 SL","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Racemic isometheptene 70 mg","genericName":"Racemic isometheptene 70 mg","slug":"racemic-isometheptene-70-mg","indication":"Other","status":"phase_1"},{"name":"SL TNX-102 at 2.4 mg","genericName":"SL TNX-102 at 2.4 mg","slug":"sl-tnx-102-at-2-4-mg","indication":"Other","status":"phase_1"},{"name":"TNX-201 35 mg","genericName":"TNX-201 35 mg","slug":"tnx-201-35-mg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Racemic isometheptene 70 mg","genericName":"Racemic isometheptene 70 mg","slug":"racemic-isometheptene-70-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SL TNX-102 at 2.4 mg","genericName":"SL TNX-102 at 2.4 mg","slug":"sl-tnx-102-at-2-4-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TNX-201 35 mg","genericName":"TNX-201 35 mg","slug":"tnx-201-35-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Tonix Pharmaceuticals reported its financial results for the fourth quarter and full year 2023, with a net loss of $34.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Tonix Pharmaceuticals Announces Collaboration with the U.S. Department of Defense to Develop a COVID-19 Vaccine","summary":"Tonix Pharmaceuticals announced a collaboration with the U.S. Department of Defense to develop a COVID-19 vaccine, with the goal of delivering a vaccine to the military by the end of 2023.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"regulatory","headline":"Tonix Pharmaceuticals Receives FDA Fast Track Designation for TNX-4300, a COVID-19 Vaccine Candidate","summary":"Tonix Pharmaceuticals received FDA Fast Track designation for TNX-4300, a COVID-19 vaccine candidate, which is currently in Phase 1 clinical trials.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQZ2Y5MUNOaHM0Mno5b1hzZlZtWUdRbno5Ykw5MFF6SjRpemxuYWpHZGdEOVNCelN0bFZOMFdnT0RHbVBmaVI3RzJSc2lUMmR2c0JoM3I1MEEwMTJEZW5QbV9rYkh2MDBJOTVjYUNlTzJYeHJEaHVMT2pYalU5eDhwSDN5bVdKZ09GMV95bV9lLU5rbkUzMFY0a1JsSVJXY2IxdmVhX1RKMHFZajA5eHpFTHZ3QTd3MGhp?oc=5","date":"2026-03-23","type":"pipeline","source":"Stock Titan","summary":"Lyme disease and mpox studies put Tonix on vaccine congress agenda - Stock Titan","headline":"Lyme disease and mpox studies put Tonix on vaccine congress agenda","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNVTZma2I2d2JmdGRzM3FReXFZZjBJNTdhaWNXc2ZoV2MwUnpSdXQwYVpBa1BfTUtLY2k0dEQ5QXVUOGNrbVptMmtaSlFJUmltOHJROEg4WHhwOGM1S1Q5NHVRNzkzQ1B2bzR4eFVsZzFsQW5HVXlzaF9fMFJpRC1NSE5WTXYwSVJwQVlHdU16WmVlQ0NWUTlpMFZhZUVTQTJoLVU1eERpNEl0alJ3?oc=5","date":"2026-03-18","type":"pipeline","source":"Stock Titan","summary":"Tonix CEO to spotlight fibromyalgia and Lyme programs in Lisbon - Stock Titan","headline":"Tonix CEO to spotlight fibromyalgia and Lyme programs in Lisbon","sentiment":"neutral"},{"date":"2026-03-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQODNEQ2hUVlg0ZExRVGNKS1loNjh5TV9zZy1qQXg4TTZvQ3dodzdKdE5CVVoyOUdGSjZ1Wjg2NTROY2M2LV9DdW04S1JKc0hlTVE1M0xkWTFvcGJkT01FcmxDSVBrdXJZMXhYM3pJQV9qekVpSktxWVprSFJCaW4wMzdQeXhiUUdGNkJ3TUVCenQxT2ptUzhNUGItVHhNdUpXUHJjb0xWYXY3eXJMN01fOGtiNkxqSXpEaF9j?oc=5","date":"2026-03-17","type":"pipeline","source":"Stock Titan","summary":"Cancer research: Tonix spotlights immuno-oncology work at AACR 2026 - Stock Titan","headline":"Cancer research: Tonix spotlights immuno-oncology work at AACR 2026","sentiment":"neutral"},{"date":"2026-03-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPMWRqcUg5djM0b1FlMXh4Ti1MNDZ4TkFYc2ZGbEFxdUY4Y0hfMjJjcVVaMnpScTEwcDZWQ3FVbC1HN242UVd0UzVHdHF4S0VXckc3MkFvekVuMXRMbzR3cU9mMTBZVkxfbG1TdFBEVnNXaWpya2hsZzd3Skd4SjB5dEEyYTczQlZRZFFUUUtrSWFxNGIzY3Bkc1FnUjByM0I1MlRnNnRhYjZyekRQX0E1enhCWmhwUmhvR3c?oc=5","date":"2026-03-12","type":"pipeline","source":"Stock Titan","summary":"First new fibromyalgia drug in 15 years sees 4,200 Tonmya prescriptions - Stock Titan","headline":"First new fibromyalgia drug in 15 years sees 4,200 Tonmya prescriptions","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: ANNUAL REPORT","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-02-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFBFZ1NzRmRrYlAxeENGaXdFdHRVSEljem5MVEhaeENTc0JFcDBMSHlLNmVJNWlzMW0waTVTemVzRHhKdUxpRDE4OHBqZk4wdzJld1lFU2FzV09oTVJxMnFoUUNZVjh1SXFpNkcyWUp2WFFRaUUyallDZ3VLZGhrUQ?oc=5","date":"2025-12-30","type":"pipeline","source":"Yahoo Finance","summary":"Tonix prices 615,025 shares at $16.26 in registered direct offering - Yahoo Finance","headline":"Tonix prices 615,025 shares at $16.26 in registered direct offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOTHBrVTFCa2M1d2IxZ0x4em5pMEh5Uk5XMnNFR0RFWWRncEZPVGxNWnVONlNvNE43bzRhV3VGYVB1S2tVcWlON2tNSWhsYmcyWll3Y1FfblhqTDdkMVlqRWRBb2hBZjhVOERoUFJBNUlmMjRTTVk4M1E5SHhCWG5TV1BRNTZPNjZac0hycVY4NWFuSzdLNXNERkZlVGxkUVphVHRWakxYcHRlV2JoUHVaMVB0dDVONjRVejJNTVpzQW8?oc=5","date":"2025-11-11","type":"earnings","source":"MarketBeat","summary":"Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Quarterly Earnings Results - MarketBeat","headline":"Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Quarterly Earnings Results","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPWDRick16elE5eGtmcTdrLUZNQUpxVkZNZmFoQUM4YkZNMjJNX2hGZEtfeEMtT2lDTVVLcDR1UEFWdVRvOHdEcnV0dl9wdDB2M3NlVmJuZEZTbXRrVGVNNzNXNS04bEVKbXVRUWkwQ2t3c2dKcTdJNHZJQUJ3ZW9VLWQ0S2F3MG43Zms3UlVXZ25GbVhUWWM2OXNORnNZdUlNMEdNRE9qTWZqUnNqR0xJNy1XdDNkUi0yd0E?oc=5","date":"2025-11-05","type":"earnings","source":"MarketBeat","summary":"Tonix Pharmaceuticals (TNXP) Projected to Post Earnings on Tuesday - MarketBeat","headline":"Tonix Pharmaceuticals (TNXP) Projected to Post Earnings on Tuesday","sentiment":"positive"}],"patents":[{"drugName":"TNX-102 SL","drugSlug":"cyclohexanone-derivative","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":3,"phaseCounts":{"phase_1":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Johnson & Johnson","GSK"],"therapeuticFocus":["Central Nervous System (CNS) Disorders","Vaccines","Immunology"],"financials":{"source":"sec_edgar","revenue":13107000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":13107000,"period":"2025-12-31"},{"value":10094000,"period":"2024-12-31"},{"value":10094000,"period":"2024-12-31"},{"value":7768000,"period":"2023-12-31"},{"value":7768000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":44486000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-124021000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":277171000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":13.55,"previousClose":13.07,"fiftyTwoWeekHigh":69.97,"fiftyTwoWeekLow":11.6,"fiftyTwoWeekRange":"11.6 - 69.97","fiftyDayAverage":15.02,"twoHundredDayAverage":24.05,"beta":1.76,"enterpriseValue":-31119408,"forwardPE":-2.6,"priceToBook":0.71,"priceToSales":14.69,"enterpriseToRevenue":-2.37,"enterpriseToEbitda":0.25,"pegRatio":0,"ebitda":-123778000,"ebitdaMargin":0,"freeCashflow":-59429000,"operatingCashflow":-99844000,"totalDebt":1309000,"debtToEquity":0.5,"currentRatio":7.42,"returnOnAssets":-35.7,"returnOnEquity":-64.5,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":3,"targetMeanPrice":54.33,"targetHighPrice":65,"targetLowPrice":34,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.1,"institutionHeldPercent":26.8,"sharesOutstanding":14205401,"floatShares":13381405,"sharesShort":2473177,"shortRatio":6.92,"shortPercentOfFloat":18.5,"epsTrailing":-14.57,"epsForward":-5.15,"revenuePerShare":1.54,"bookValue":19.17,"officers":[{"age":67,"name":"Dr. Seth  Lederman M.D.","title":"Co-Founder, President, CEO & Chairman"},{"age":null,"name":"Mrs. Jessica Edgar Morris","title":"Chief Operating Officer"},{"age":59,"name":"Dr. Gregory M. Sullivan M.D.","title":"Chief Medical Officer & Secretary"},{"age":56,"name":"Ms. Siobhan  Fogarty B.Sc., M.Sc.","title":"Chief Technical Officer"},{"age":null,"name":"Ms. Irina  Ishak","title":"General Counsel"},{"age":null,"name":"Dr. Darryl  Rideout Ph.D.","title":"Executive Vice President of Experimental Chemistry"},{"age":null,"name":"Dr. Sina  Bavari Ph.D.","title":"Executive Vice President of Infectious Disease Research & Development"},{"age":null,"name":"Dr. Zeil  Rosenberg M.D., M.P.H.","title":"Executive Vice President of Medical"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.tonixpharma.com","phone":"862 799 8599"}}